首页> 美国卫生研究院文献>ecancermedicalscience >Highlights from the 2019 International Aspirin Foundation Scientific Conference Rome 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention
【2h】

Highlights from the 2019 International Aspirin Foundation Scientific Conference Rome 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention

机译:2019年国际阿司匹林基金会科学会议的要点2019年6月28日罗马:抗血栓治疗对预防心血管疾病的益处和风险

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

At the 2019 International Aspirin Foundation Scientific Conference ‘Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention’, held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.
机译:在意大利罗马举行的2019年国际阿司匹林基金会科学会议``抗栓治疗的益处和风险预防''上,国际专家寻求讨论和辩论用于心血管疾病二级预防(CVD)的最佳抗栓策略寻求有关阿司匹林用于主要疾病预防的剂量和目标人群的协议。获得最好的证据来支持诊所中的现实生活决策可能很复杂,而个性化管理以平衡不同疾病预防策略的风险和收益似乎是最好的方法。希望未来的决策工具和生物标记物将有助于对最有可能受益的人群进行直接治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号